Pluristem Represents An Undervalued Player With Upside For The Long-Term Investor, Says H.C. Wainwright
In a research note released today, H.C. Wainwright analyst Reni Benjamin reiterated a Buy rating on Pluristem Therapeutics (NASDAQ:PSTI) with a $4 price target, which represents a 51% upside from where the stock is currently trading.
Benjamin wrote, “Pluristem’s lead product, PLX-PAD, is being developed as a cell therapy for critical limb ischemia (CLI), intermittent claudication (IC), soft tissue regeneration, and pulmonary arterial hypertension (PAH). A Phase 2 study in IC is expected to complete enrollment in mid-2015, around the same time a pivotal Phase 2/3 CLI trial in Asia and Europe is scheduled to begin. Additionally, the company finalized the manufacturing process for its second product, PLX-RAD, with the potential to enter the clinic in 2015. Given the company’s successful history of forging partnerships to offset developmental costs, a manufacturing process that has been approved for pivotal trials by the FDA and other regulatory agencies, and a cash position of $51 MM, we believe Pluristem Therapeutics represents an undervalued player with upside for the long-term investor.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Reni Benjamin has a total average return of -3.3% and a 35.4% success rate. Benjamin has a -11.7% average return when recommending PSTI, and is ranked #3065 out of 3384 analysts.